Originally published by our sister publication, Infectious Disease Special Edition
By Tom Rosenthal
This story was updated on June 8 to include a link to an FDA document about patient eligibility.
Clinicians should not avoid prescribing nirmatrelvir-ritonavir (Paxlovid, Pfizer) to treat mild to moderate COVID-19 out of fear of or confusion over potential drug–drug interactions, Infectious Diseases Society of America (IDSA) experts said in a media briefing to promote the organization’s